Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Oct 1.

Published in final edited form as: BJU Int. 2017 Jun 29;120(4):576–583. doi: 10.1111/bju.13924

Fig. 3 — Effects of anti-VEGF pre-treatment on cyclophosphamide (CYP)-induced changes in spontaneous micturition behavior. A: Sample VAS blots from a saline pre-treated mouse. B: Sample blots from an anti-VEGF pre-treatment mouse. C: Comparison of urinary frequency with anti-VEGF (10 mg/kg) pre-treatment versus saline pre-treatment, prior to CYP (150 mg/kg i.p.) administration. Data over the course of two hours were plotted for each time-point. D: Comparison of mean voided volume. There was no difference between the saline (n=6) and anti-VEGF (n=8) pre-treatment groups at the various time points (p>0.05 in all comparison).

Fig. 3 — Effects of anti-VEGF pre-treatment on cyclophosphamide (CYP)-induced changes in spontaneous micturition behavior. A: Sample VAS blots from a saline pre-treated mouse. B: Sample blots from an anti-VEGF pre-treatment mouse. C: Comparison of urinary frequency with anti-VEGF (10 mg/kg) pre-treatment versus saline pre-treatment, prior to CYP (150 mg/kg i.p.) administration. Data over the course of two hours were plotted for each time-point. D: Comparison of mean voided volume. There was no difference between the saline (n=6) and anti-VEGF (n=8) pre-treatment groups at the various time points (p>0.05 in all comparison).